まとめ
フック効果により免疫グロブリンA(IgA)値が偽低値となり、多発性骨髄腫をマスクする可能性がある。正確なIgA測定と診断には希釈試験が不可欠である。
科学分野:
- 臨床化学
- 免疫学
- 診断医学
背景:
- 免疫グロブリンA(IgA)は、免疫機能および多発性骨髄腫診断の重要なバイオマーカーである。
- フック効果は、高濃度で偽低値のIgA結果を引き起こし、疾患をマスクする可能性がある。
- この現象は、誤診または診断見落としのリスクをもたらす。
研究 の 目的:
- フック効果によるIgAの偽減少の一例を報告する。
- IgA検査におけるフック効果の臨床的意義を強調する。
- 正確なIgA定量化の重要性を強調する。
主な方法:
- IgAの偽減少患者の症例報告。
- IgA、IgM、IgGレベルと血清グロブリンの分析。
- 連続希釈後のサンプル再検査による真のIgA濃度の決定。
主要な成果:
- 初期IgA検出値は6.89 g/Lであり、血清グロブリン値(52.5 g/L)よりも著しく低かった。
- 希釈後の再検査により、真のIgA値は37.25 g/Lであることが明らかになった。
- この乖離は、フック効果によるIgAの偽減少を確認した。
結論:
- IgAの結果と血清グロブリンレベルとの乖離は、フック効果の調査を正当化する。
- 臨床検査担当者は、正確なIgAレベルを得るために希釈再検査を実施しなければならない。
- 多発性骨髄腫の誤診および診断見落としを防ぐためには、正確なIgA測定が不可欠である。
関連する概念動画
Transcytosis of IgG
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...


